三重激动剂 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
==== Sabellid polychaetes ==== The sabellid polychaetes, or feather duster worms, have cartilage tissue with cellular and matrix specialization supporting their tentacles. They present two distinct extracellular matrix regions. These regions are an acellular fibrous region with a high collagen content, called cartilage-like matrix, and collagen lacking a highly cellularized core, called osteoid-like matrix. The cartilage-like matrix surrounds the osteoid-like matrix. The amount of the acellular fibrous region is variable. The model organisms used in the study of cartilage in sabellid polychaetes are Potamilla species and Myxicola infundibulum.
==== Deposition ==== The extracellular matrix of bone is laid down by osteoblasts, which secrete both collagen and ground substance. These cells synthesise collagen alpha polypeptide chains and then secrete collagen molecules. The collagen molecules associate with their neighbors and crosslink via lysyl oxidase to form collagen fibrils. At this stage, they are not yet mineralized, and this zone of unmineralized collagen fibrils is called "osteoid". Around and inside collagen fibrils calcium and phosphate eventually precipitate within days to weeks becoming then fully mineralized bone with an overall carbonate substituted hydroxyapatite inorganic phase. In order to mineralise the bone, the osteoblasts secrete alkaline phosphatase, some of which is carried by vesicles. This cleaves the inhibitory pyrophosphate and simultaneously generates free phosphate ions for mineralization, acting as the foci for calcium and phosphate deposition. Vesicles may initiate some of the early mineralization events by rupturing and acting as a centre for crystals to grow on. Bone mineral may be formed from globular and plate structures, and via initially amorphous phases.
=== Goodpasture syndrome === The alpha-3 subunit (COL4A3) of collagen IV is thought to be the antigen implicated in Goodpasture syndrome, wherein the immune system attacks the basement membranes of the glomeruli and the alveoli upon the antigenic site on the alpha-3 subunit becoming unsequestered due to environmental exposures. Goodpasture syndrome presents with nephritic syndrome and hemoptysis. Microscopic evaluation of biopsied renal tissue will reveal linear deposits of Immunoglobulin G by immunofluorescence. This is classically in young adult males.
Promethium forms only one stable oxidation state, +3, in the form of ions; this is in line with other lanthanides. Promethium can also form the +2 oxidation state. Thermodynamic properties of Pm2+ suggests that the dihalides are stable, similar to NdCl2 and SmCl2.
Sources: en.wikipedia.org
Swedish foreign affairs commentator and terrorism expert Wolfgang Hansson compared Trump's actions to Russian hybrid warfare, stating that "Trump realised that taking over Greenland militarily would be expensive, risky, and look very bad, but hybrid warfare is cheap and easy to deny".
== Further reading == Brandoni, Diego; Scillato Yané, Gustavo J.; Miño Boilini, Ángel R.; Favotti, Emmanuel (2016). "Los Tardigrada (Mammalia, Xenarthra) de Argentina: diversidad, evolución y biogeografía" (PDF). Contribuciones del MACN. _: 263–274. Retrieved 2018-10-08. Cuvier, G. (1796): Notice sur le squelette d'une très grande espèce de quadrupède inconnue jusqu'à présent, trouvé au Paraguay, et déposé au cabinet d'histoire naturelle de Madrid. Magasin encyopédique, ou Journal des Sciences, des Lettres et des Arts (1): 303–310; (2): 227–228. De Iuliis, G. & Cartelle, C. (1999): A new giant megatheriine ground sloth (Mammalia: Xenarthra: Megatheriidae) from the late Blancan to early Irvingtonian of Florida. Zool. J. Linn. Soc. 127(4): 495–515. Harrington, C.R. (1993): Yukon Beringia Interpretive Center - Jefferson's Ground Sloth. Retrieved 2008-JAN-24. Hogan, C.M. (2008): Cueva del Milodon, Megalithic Portal. Retrieved 2008-APR-13 Kurtén, Björn and Anderson, Elaine (1980): Pleistocene Mammals of North America. Columbia University Press, New York. ISBN 0-231-03733-3 McKenna, Malcolm C. & Bell, Susan K. (1997): Classification of Mammals Above the Species Level. Columbia University Press, New York. ISBN 0-231-11013-8 Nowak, R.M. (1999): Walker's Mammals of the World (Vol. 2). Johns Hopkins University Press, London. White, J.L. (1993): Indicators of locomotor habits in Xenarthrans: Evidence for locomotor heterogeneity among fossil sloths. Journal of Vertebrate Paleontology, 13(2): 230–242. White, J.L.; MacPhee, R.D.E. (2001).
Some example ionotropic (LGIC) and metabotropic (specifically, GPCRs) receptors are shown in the table below. The chief neurotransmitters are glutamate and GABA; other neurotransmitters are neuromodulatory. This list is by no means exhaustive.
Sources: en.wikipedia.org
== Cancer == Hsp70 is overexpressed in melanoma and underexpressed in renal cell cancer. In breast cancer cell line (MCF7) has been found that not only Hsp90 interacted with estrogen receptor alpha (ERα) but also Hsp70-1 and Hsc70 interacted with ERα too. Given the role of heat shock proteins as an ancient defense system for stabilizing cells and eliminating old and damaged cells, this system has been co-opted by cancer cells to promote their growth. Increased Hsp70 in particular has been shown to inhibit apoptosis of cancer cells, and increased Hsp70 has been shown to be associated with or directly induce endometrial, lung, colon, prostate, and breast cancer, as well as leukemia. Hsp70 in cancer cells may be responsible for tumorigenesis and tumor progression by providing resistance to chemotherapy. Inhibition of Hsp70 has been shown to reduce the size of tumors and can cause their complete regression. Hsp70/Hsp90 is a particularly attractive target for therapeutics, because it is regulated by the inhibition of its ATPase activity, while other HSPs are regulated by nucleotides. Several inhibitors have been designed for Hsp70 that are currently in clinical trials, though as of now HSP90 inhibitors have been more successful. In addition, Hsp70 has been shown to be a regulator of the immune system, activating the immune system as an antigen. Thus, tumor-derived Hsp70 has been suggested as a potential vaccine or avenue to target for immunotherapy.
The London Borough of Brent was created in 1965 under the London Government Act 1963, covering the combined area of the former Municipal Borough of Wembley and the Municipal Borough of Willesden. The area was transferred from Middlesex to Greater London to become one of the 32 London Boroughs. The borough of Willesden had evolved from a local government district created in 1874 for the parish of Willesden. Such districts were reconstituted as urban districts under the Local Government Act 1894. To coincide with the 1894 Act coming into force, an urban district called Wembley was created, covering the two parishes of Kingsbury and Wembley, the latter being created at the same time from areas formerly in the ancient parish of Harrow on the Hill. Kingsbury seceded from the Wembley Urban District in 1900 to become its own urban district, but was reunited with the Wembley Urban District in 1934. Willesden was incorporated to become a municipal borough in 1933, as was Wembley in 1937. The modern borough takes its name from the River Brent which runs through the borough and separated the former boroughs of Wembley and Willesden.
== Medical uses == Total parenteral nutrition (TPN) is provided when the gastrointestinal tract is nonfunctional because of an interruption in its continuity (it is blocked, or has a leak – a fistula) or because its absorptive capacity is impaired. It has been used for comatose patients, although enteral feeding is usually preferable, and less prone to complications. Parenteral nutrition is used to prevent malnutrition in patients who are unable to obtain adequate nutrients by oral or enteral routes. The Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition recommends waiting until the seventh day of hospital care to administer parenteral nutrition.
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。